Vanguard Group Inc Monopar Therapeutics Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MNPR
# of Institutions
16Shares Held
390KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny192KShares$157,7520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA41.2KShares$33,7830.0% of portfolio
-
Hrt Financial LP New York, NY32.1KShares$26,3320.0% of portfolio
-
Gerber, LLC Columbus, OH28KShares$22,9640.02% of portfolio
-
Virtu Financial LLC New York, NY23.8KShares$19,5380.0% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $10.4M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...